Advances in venom peptide drug discovery: where are we at and where are we heading?
Quick Facts
What This Study Found
Multiple venom-derived peptide drugs are FDA-approved, and toxin-driven discovery approaches are expanding the clinical pipeline with candidates from previously unstudied venomous species.
Key Numbers
Multiple FDA-approved drugs; exenatide from Gila monster; ziconotide from cone snail; toxin-driven discovery expanding pipeline; applications in diabetes, pain, and more
How They Did This
Expert review of FDA-approved venom-derived peptide drugs, peptides in preclinical and clinical development, drug development challenges, and emerging discovery technologies.
Why This Research Matters
Venoms are one of nature's richest sources of drug leads. With most venomous species still unexplored, the potential for new therapies is enormous. Advances in technology are making it practical to tap into this resource.
What This Study Doesn't Tell Us
Expert review, not systematic. Focus on peptides may underestimate non-peptide venom components. Drug development challenges (stability, delivery) remain significant hurdles for many candidates.
Trust & Context
- Original Title:
- Advances in venom peptide drug discovery: where are we at and where are we heading?
- Published In:
- Expert opinion on drug discovery, 16(10), 1163-1173 (2021)
- Authors:
- Smallwood, Taylor B, Clark, Richard J(4)
- Database ID:
- RPEP-05775
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05775APA
Smallwood, Taylor B; Clark, Richard J. (2021). Advances in venom peptide drug discovery: where are we at and where are we heading?. Expert opinion on drug discovery, 16(10), 1163-1173. https://doi.org/10.1080/17460441.2021.1922386
MLA
Smallwood, Taylor B, et al. "Advances in venom peptide drug discovery: where are we at and where are we heading?." Expert opinion on drug discovery, 2021. https://doi.org/10.1080/17460441.2021.1922386
RethinkPeptides
RethinkPeptides Research Database. "Advances in venom peptide drug discovery: where are we at an..." RPEP-05775. Retrieved from https://rethinkpeptides.com/research/smallwood-2021-advances-in-venom-peptide
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.